市場調査レポート

商品コード

1800821

肺動脈性肺高血圧症治療薬の市場レポート：薬剤クラス別、投与経路別、エンドユーザー別、地域別、2025～2033年

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 447,600円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 596,850円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 746,100円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.25円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の肺動脈性肺高血圧症（PAH）治療薬の市場規模は2024年に80億米ドルに達しました。今後、IMARC Groupは、市場が2033年までに120億米ドルに達し、2025～2033年にかけて4.4%の成長率（CAGR）を示すと予測しています。同市場は、標的治療の進歩、PAHの有病率の増加、認知度の向上などを主な要因として大きな成長を遂げています。研究開発（R&D）活動の拡大も、世界的に市場の明るい展望を生み出しています。

肺動脈性肺高血圧症治療薬市場の動向

併用療法の増加

肺動脈性肺高血圧症（PAH）の治療効果を高めるために、併用療法を採用する医師が増えています。異なる治療クラスの薬剤を組み合わせて処方することで、PAHに関与する複数の生物学的経路を標的とします。この多面的なアプローチは、症状を管理し、病気の進行を遅らせ、全体的な患者の転帰をより効果的に改善するのに役立ちます。さらに、併用療法は個々の薬剤の投与量を減らすことができ、副作用を軽減し、患者のアドヒアランスを高める可能性があります。臨床エビデンスがその利点を裏付けていることから、併用治療はPAH管理における標準治療となりつつあり、市場の成長と技術革新を牽引しています。例えば、2024年3月、Johnson & JohnsonのOPSYNVI（R）（マシテンタンとタダラフィル）は、成人の肺動脈性肺高血圧症（PAH）患者に対する初の1日1回単剤併用療法として米国FDAから承認されました。この承認は、有意な肺血行動態の改善を示した第3相A DUE試験の成功に基づいています。OPSYNVI（R）は、確立された2つの治療を1錠にまとめたもので、早期併用療法に関する臨床ガイドラインの推奨に沿ったものです。

革新的治療への注目の高まり

肺動脈性肺高血圧症（PAH）における革新的治療への注目の高まりは、疾患の根本原因に対処することを目的とした遺伝子治療や標的生物学的製剤の探求を後押ししています。遺伝子治療は、PAHに関与する遺伝的因子を修正する可能性を秘めており、単なる対症療法ではなく長期的な解決策を提供します。一方、標的生物学的製剤は、疾患の進行に関与する特定の分子経路に焦点を当て、より個別化された効果的な治療を可能にします。これらの新しいアプローチは、疾患改善における重要なブレークスルーをもたらし、PAH患者の生存率と全体的なQOLを改善する可能性があります。これに伴い、2024年8月、Liquidia CorporationのYUTREPIA(TM)（一般名トレプロスチニル）吸入用粉末は、成人の肺動脈性肺高血圧症（PAH）および間質性肺疾患に伴う肺高血圧症（PH-ILD）の治療薬として、米国FDAより暫定承認を取得しました。今回の承認は、YUTREPIAの安全性と有効性を実証した第3相INSPIRE試験に基づいています。同社は、PAHおよびPH-ILD患者のアンメットニーズに対応するため、早期に最終承認を取得する予定です。

患者中心ケアとデジタルヘルス

患者中心ケアへの取り組みとデジタルヘルスツールの統合は、治療のアドヒアランスとアウトカムを向上させることで、肺動脈性肺高血圧症治療薬市場のダイナミクスに影響を与えています。モバイルアプリやウェアラブルデバイスを含むデジタルヘルスツールは、心拍数や酸素レベルなどのバイタルサインの継続的なモニタリングを可能にします。さらに、デジタルプラットフォームは患者と医療チーム間のシームレスなコミュニケーションを促進し、全体的な疾病管理を強化します。このような統合は、患者の転帰を改善するだけでなく、患者がPAHの管理に積極的な役割を果たすことを促し、QOLの向上とヘルスケア提供の効率化につながります。さらに、AJMCが2024年に発表した論文では、ツイン技術が肺高血圧症（PH）治療に革命をもたらす可能性が示唆されています。この技術は、患者のバーチャルモデルを作成し、病気の進行をシミュレーションし、治療結果を予測するものです。この研究では、個別化医療とインシリコ臨床試験の可能性が示されており、従来の臨床試験に伴う時間とコストを削減できる可能性があります。このようなデジタルヘルスとデジタルツイン技術の進歩は、前向きな肺動脈性肺高血圧症治療薬市場の展望を生み出し、成長を促進し、患者ケアを改善しています。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ

第10章 SWOT分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章価格分析

第14章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Actelion Pharmaceuticals Ltd（Johnson & Johnson）
- Arena Pharmaceuticals Inc.
- AstraZeneca PLC
- Bayer Aktiengesellschaft
- Daiichi Sankyo Company Limited
- Gilead Science Inc.
- GlaxoSmithKline PLC
- Merck KGaA
- Novartis International AG
- Pfizer Inc.
- United Therapeutics Corporation

図表

List of Figures

Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2024
Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2024
Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2024
Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2024
Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players

Product Code: SR112025A2399

The global pulmonary arterial hypertension (PAH) drugs market size reached USD 8.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033. The market is experiencing significant growth mainly driven by advancements in targeted therapies, increasing prevalence of PAH and growing awareness. Expanding research and development (R&D) efforts are also creating a positive outlook for the market further across the world.

Pulmonary Arterial Hypertension Drugs Market Trends:

Increased Use of Combination Therapies

Physicians are increasingly adopting combination therapies to enhance treatment efficacy in Pulmonary Arterial Hypertension (PAH). By prescribing a mix of drugs from different therapeutic classes, they target multiple biological pathways involved in PAH. This multifaceted approach helps to manage symptoms, slow disease progression, and improve overall patient outcomes more effectively. Additionally, combination therapies can allow for lower doses of individual medications, potentially reducing side effects and enhancing patient adherence. As clinical evidence supports their benefits, combination treatments are becoming the standard of care in PAH management, driving market growth and innovation. For instance, in March 2024, Johnson & Johnson's OPSYNVI(R) (macitentan and tadalafil) was approved by the U.S. FDA as the first once-daily single-tablet combination therapy for adults with pulmonary arterial hypertension (PAH). This approval is based on the successful Phase 3 A DUE study, which showed significant pulmonary hemodynamic improvement. OPSYNVI(R) combines two established treatments into a single tablet, aligning with clinical guideline recommendations for early combination therapy.

Rising Focus on Innovative Therapies

The rising focus on innovative therapies in Pulmonary Arterial Hypertension (PAH) is driving the exploration of gene therapies and targeted biologics, which aim to address the root causes of the disease. Gene therapies hold the potential to modify genetic factors involved in PAH, offering a long-term solution rather than just symptom management. Targeted biologics, on the other hand, focus on specific molecular pathways contributing to disease progression, allowing for more personalized and effective treatments. These novel approaches could lead to significant breakthroughs in disease modification, improving survival rates and overall quality of life for PAH patients. In line with this, in August 2024, Liquidia Corporation's YUTREPIA(TM) (treprostinil) inhalation powder received tentative approval from the U.S. FDA to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is based on the Phase 3 INSPIRE trial, which demonstrated the safety and efficacy of YUTREPIA. The company plans to seek final approval at the earliest to address the unmet needs of PAH and PH-ILD patients.

Patient-Centered Care and Digital Health

Patient-centered care initiatives and the integration of digital health tools are influencing the pulmonary arterial hypertension drugs market dynamics by enhancing treatment adherence and outcomes. Digital health tools, including mobile apps and wearable devices, enable continuous monitoring of vital signs such as heart rate and oxygen levels. Additionally, digital platforms facilitate seamless communication between patients and medical teams, enhancing overall disease management. This integration not only improves patient outcomes but also empowers individuals to take an active role in managing their PAH, leading to increased quality of life and more efficient healthcare delivery. Moreover, in an article published by AJMC in 2024, it was suggested that twin technology has the potential to revolutionize pulmonary hypertension (PH) treatment. This technology involves creating virtual models of patients to simulate disease progression and predict treatment outcomes. The study emphasizes the potential for personalized care and in silico clinical trials, which could reduce the time and costs associated with traditional trials. These advancements in digital health and twin technology are creating a positive pulmonary arterial hypertension drugs market outlook, driving growth and improving patient care.

Pulmonary Arterial Hypertension (PAH) Drugs Market Segmentation:

Breakup by Drug Class:

Endothelin Receptor Antagonists (ERAs)
Vasodilators
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Calcium Channel Blockers (CCBs)
Prostacyclin and Prostacyclin Analogs
Others

Prostacyclin and Prostacyclin Analogs accounts for the majority of the market share

Prostacyclin and prostacyclin analogs dominate the pulmonary arterial hypertension (PAH) drugs market, accounting for the largest market share due to their critical role in managing the disease. These medications work by dilating blood vessels, reducing vascular resistance, and inhibiting platelet aggregation, which effectively lowers blood pressure in the pulmonary arteries. Their proven efficacy in improving exercise capacity and delaying disease progression makes them a cornerstone of PAH therapy. Additionally, the availability of various administration forms, such as intravenous, subcutaneous, and inhaled options, enhances their accessibility and convenience for patients. Ongoing advancements and the introduction of newer analogs further solidify their leading position, driving sustained pulmonary arterial hypertension drugs market growth.

Breakup by Route of Administration:

Inhalation
Injectable
Oral Administration

Oral Administration holds the largest share of the industry

Oral administration holds the largest share of the pulmonary arterial hypertension (PAH) drugs market due to its significant advantages in patient convenience and adherence. Oral medications are easy to administer, non-invasive, and can be taken at home without the need for specialized medical facilities, making them highly attractive for long-term treatment. This ease of use enhances patient compliance, which is crucial for managing a chronic condition like PAH. Additionally, advancements in pharmaceutical formulations have improved the efficacy and safety profiles of oral PAH drugs, thereby reducing side effects and increasing their appeal. For instance, in December 2023, Granules obtained approval from the U.S. Food and Drug Administration for its generic version of Viatris Specialty's Revatio, a treatment for pulmonary arterial hypertension (PAH). The product is bioequivalent and therapeutically equivalent to Viatris's Sildenafil for oral suspension, 10 mg/ml. Granules stated that the drug is intended to enhance exercise ability and delay clinical worsening in PAH patients.

Breakup by End User:

Hospitals
Clinics
Others

Hospitals are a primary end user in the Pulmonary Arterial Hypertension (PAH) drugs market, playing a crucial role in diagnosis, treatment, and ongoing management of the condition. Equipped with advanced diagnostic tools and specialized cardiology and pulmonology departments, hospitals facilitate the accurate identification of PAH, enabling timely and effective intervention. They administer a wide range of PAH medications, including advanced biologics and combination therapies, ensuring comprehensive patient care. Additionally, hospitals often participate in clinical trials and research initiatives, driving innovation and the development of new treatments. The centralized infrastructure and multidisciplinary approach in hospitals significantly contribute to the growth and adoption of PAH drugs in the market.

Clinics are essential end users in the Pulmonary Arterial Hypertension (PAH) drugs market, providing accessible and continuous care for patients with PAH. These outpatient facilities offer routine monitoring, medication management, and personalized treatment plans, enhancing patient adherence and outcomes. Clinics often collaborate with specialists to deliver comprehensive care, utilizing a variety of PAH drugs, including oral therapies and injectable medications. The convenience and localized presence of clinics make them pivotal in managing chronic conditions like PAH, ensuring that patients receive timely adjustments to their treatment regimens. Additionally, clinics contribute to market growth by increasing the distribution channels for PAH medications and fostering patient education and support initiatives.

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America leads the market, accounting for the largest pulmonary arterial hypertension drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pulmonary arterial hypertension (PAH) drugs.

North America leads the Pulmonary Arterial Hypertension (PAH) drugs market, accounting for the largest market share due to several key factors. The region benefits from a highly advanced healthcare infrastructure and widespread access to specialized medical facilities, enabling effective diagnosis and treatment of PAH. According to pulmonary arterial hypertension drugs market overview, the rising prevalence of cardiovascular and respiratory diseases drives the demand for PAH medications across the region. Additionally, North America is home to major pharmaceutical companies that invest heavily in research and development (R&D), fostering innovation and the introduction of new therapies. Favorable regulatory frameworks and substantial healthcare funding further support market growth. Moreover, increased awareness and education about PAH contribute to the early detection and higher treatment rates, solidifying North America's dominant market position. For instance, in September 2023, researchers at Vanderbilt University developed a new drug, VU6047534, to treat pulmonary arterial hypertension without serious neurological side effects. The drug targets serotonin 2B receptors in the heart and lungs, promoting organ healing and potentially reversing damage from heart attacks. The compound, designed to stay out of the brain, represents a promising therapy for PAH. The research was funded by the National Institutes of Health and Vanderbilt University.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pulmonary arterial hypertension (PAH) drugs industry include Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The Pulmonary Arterial Hypertension (PAH) drugs market is highly competitive, with numerous pharmaceutical companies vying for market share through the development of innovative therapies. The market is characterized by a growing focus on advanced treatments, such as combination therapies and targeted biologics, which offer improved efficacy and patient outcomes. Companies are investing heavily in research and development to introduce novel drugs and enhance existing treatments. Pricing strategies, regulatory approvals, and patent expirations significantly influence market dynamics. Additionally, the increasing availability of generics intensifies competition, while market leaders leverage strong distribution networks and clinical trial results to maintain their positions.

Key Questions Answered in This Report

1.What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2024?
2.What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2025-2033?
3.What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?
4.What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?
5.What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?
6.What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?
7.What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?
8.Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class

6.1 Endothelin Receptor Antagonists (ERAs)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Vasodilators
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Soluble Guanylate Cyclase (sGC) Stimulators
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Calcium Channel Blockers (CCBs)
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Prostacyclin and Prostacyclin Analogs
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

7.1 Inhalation
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Injectable
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Oral Administration
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Arena Pharmaceuticals Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 AstraZeneca PLC
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Bayer Aktiengesellschaft
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Daiichi Sankyo Company Limited
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Gilead Science Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 GlaxoSmithKline PLC
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Merck KGaA
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Novartis International AG
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
- 14.3.10 Pfizer Inc.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 United Therapeutics Corporation
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis

肺動脈性肺高血圧症治療薬の市場レポート：薬剤クラス別、投与経路別、エンドユーザー別、地域別、2025～2033年

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2025-2033

肺動脈性肺高血圧症治療薬市場の動向

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の肺動脈性高血圧症（PAH）治療薬市場

第6章 市場内訳：薬剤クラス別

第7章 市場内訳：投与経路別

第8章 市場内訳：エンドユーザー別

第9章 市場内訳：地域別

第10章 SWOT分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 価格分析

第14章 競合情勢